Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AXA1665 in Subjects With Liver Cirrhosis and Prior Overt Hepatic Encephalopathy (EMMPOWER)
Conditions
Interventions
AXA1665
Placebo
Locations
40
United States
University of California, San Francisco (UCSF)
San Francisco, California, United States
OMEGA Research Consultants
DeBary, Florida, United States
UF Hepatology Research at CTRB
Gainesville, Florida, United States
Homestead Associates in Research
Miami, Florida, United States
University of Miami
Miami, Florida, United States
Indiana University School of Medicine
Indianapolis, Indiana, United States
Start Date
June 29, 2021
Primary Completion Date
June 30, 2022
Completion Date
June 30, 2022
Last Updated
July 27, 2022
NCT06052176
NCT04073290
NCT04014413
NCT06368895
NCT03420482
NCT06987968
Lead Sponsor
Axcella Health, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions